Read more

September 27, 2019
2 min read
Save

Algorithm predicts diabetic retinopathy progression

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A deep learning algorithm developed by Genentech and Roche researchers predicts a patient’s diabetic retinopathy progression using color fundus photographs acquired at a single visit, according to a study.

Perspective from Rishi P. Singh, MD

“Our deep learning pilot study shows the potential for a tool that is highly accurate in predicting diabetic retinopathy progression at an individual patient level in a single doctor visit. Such a tool could help inform the patient’s treatment strategy — earlier treatment depending on the risk for fast progression — in order to protect and preserve their vision,” study author Zdenka Haskova, MD, PhD, medical director in clinical ophthalmology at Genentech, told Healio.com/OSN.

The retrospective study analyzed stereoscopic seven-field central fundus photographs obtained from eyes in the RIDE and RISE phase 3 studies at baseline. The eyes were treatment-naive to anti-VEGF therapy. Researchers generated algorithms from these data sets to predict worsening in untreated eyes from baseline over a period of 2 years.

Researchers then used seven-field central fundus photographs acquired from patients with diabetic retinopathy to train deep learning models to predict a two-step or more worsening on the ETDRS diabetic retinopathy severity scale over 2 years.

Worsening was predicted with an area under the curve of 0.68 ±0.13, a sensitivity of 66% and a specificity of 77% at 6 months. At 12 months, AUC was 0.79 ± 0.05, sensitivity 91% and specificity 65%. At 24 months, worsening was predicted with an AUC of 0.77 ± 0.04, a sensitivity of 79% and a specificity of 72%.

“This type of predictive algorithm could help patients get the individualized care they need, as their ophthalmologists could potentially tailor a patient’s treatment strategy knowing whether they are at risk for faster diabetic retinopathy progression,” Haskova said. – by Robert Linnehan

Disclosure: Haskova reports she is an employee and shareholder of Genentech.